Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Stephanie Pollock

MSc., D.Phil.

Clinical Trial Coordinator

I am a Clinical Trial Coordinator working on OPTiMISE-X, SHIP, and most recently the OPTIMISE2 trial - investigating anti-hypertensive medication reduction in over 75s at risk of serious adverse events.

I have been part of the Oxford PC-CTU since May 2022. 

Originally from Montreal, Canada, I have over 10 years research experience in both industry and academic settings. 

Following a postdoctoral fellowship at the University of Oxford, Antiviral Drug Discovery Unit, I took on the role of HCV Project Leader for United Therapeutics (Chertsey, UK) followed by R&D Scientist and Project Manager for ProImmune Ltd. (Oxford, UK). My D.Phil work in the Department of Biochemistry, University of Oxford, focused on the development of liposome-based antiviral therapies, mainly for the treatment of HIV and HCV.